Atossa Therapeutics Inc's Comment on Sales, Marketing and Customers
The company is engaged in the development and commercialization of therapeutics, including (Z)-endoxifen for the treatment of breast cancer and Duchenne muscular dystrophy (DMD). Its operations involve various risks and factors that impact these activities.
Atossa Therapeutics, in collaboration with Quantum Leap Healthcare Collaborative, has initiated a groundbreaking clinical trial, the I-SPY 2 study, to evaluate the neoadjuvant potential of (Z)-endoxifen in combination with the cyclin-dependent kinase 4/6 (CDK4/6) inhibitor abemaciclib for patients diagnosed with estrogen receptor-positive (ER+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer. This novel approach aims to address an urgent clinical need for effective treatment strategies in high-risk patients. This article discusses the significance of the trial, the mechanisms of action for the investigational therapies, and the continuing evolution of breast cancer treatment para...
Atossa Therapeutics, a clinical-stage biopharmaceutical company focused on breast cancer treatment, has announced protocol changes for a clinical trial evaluating the combination of their proprietary drug, (Z)-endoxifen, and abemaciclib (VERZENIO). The study aims to investigate the neoadjuvant treatment potential of this combination for women with newly diagnosed Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer. This development follows the initiation of a separate study and the successful completion of a five-year (Z)-endoxifen treatment program under FDA-approved expanded access for a pre-menopausal patient.Atossa Therapeutics, in collaboration with...
Atossa Therapeutics Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment ModelSeattle, May 28, 2024 - Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company focused on breast cancer treatment, has announced its support for a new Phase 2 study aimed at validating an innovative artificial intelligence-driven breast cancer risk assessment model. The study, known as the SMART (Stockholm MAmmography Risk stratified Trial), will utilize an individualized, imaging-based screening model to identify women who are at the highest risk of developing breast cancer within the next two years.Breast cancer is the most prevalent cancer among wom...
Atossa Therapeutics, a clinical-stage biopharmaceutical company specializing in innovative oncology treatments, has partnered with Quantum Leap Healthcare Collaborative to launch a groundbreaking clinical study. This trial aims to evaluate the potential of Atossa s proprietary (Z)-endoxifen in combination with abemaciclib (VERZENIO), a prominent cyclin-dependent kinase (CDK) 4/6 inhibitor developed by Eli Lilly and Company. By focusing on women with ER+/HER2- breast cancer, this study endeavors to address significant unmet medical needs in the field of breast cancer treatment.Facts:1. Atossa Therapeutics, Inc. and Quantum Leap Healthcare Collaborative announce the initiation of a new clinical trial.2. The st...
Data from Atossa s Phase 2 EVANGELINE Clinical Trial to be Presented at AACR Annual MeetingAtossa Therapeutics, Inc. is set to present data from the 40mg pharmacokinetic (PK) run-in cohort of its Phase 2 EVANGELINE study at the upcoming American Association for Cancer Research (AACR) Annual Meeting. The event will take place from April 5-10, 2024, in San Diego, California. The EVANGELINE study focuses on investigating (Z)-endoxifen as a neoadjuvant treatment for premenopausal women with Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer.Atossa Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative medicines to addr...
Atossa Therapeutics Inc’s Comment on Sales, Marketing and Customers
The company is engaged in the development and commercialization of therapeutics, including (Z)-endoxifen for the treatment of breast cancer and Duchenne muscular dystrophy (DMD). Its operations involve various risks and factors that impact these activities.
Sources:
Atossa Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Atossa Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Atossa Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
